

## Januvia - (EQ 25, 50, 100 MG BASE; Tablet)

|                              |                                                                                                                                 |                             |                     |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Sitagliptin Phosphate                                                                                                           | <b>Innovator</b>            | Merck               |
| <b>Dosage</b>                | EQ 25, 50, 100 MG BASE; Tablet                                                                                                  | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | More Than 5                                                                                                                     | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5                                                                                                                     | <b>Tentative Approvals</b>  | More Than 5         |
| <b>Final Approvals</b>       | Less Than 5                                                                                                                     | <b>Generic Launches</b>     | Less Than 5         |
| <b>Indication</b>            | It Control high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                             |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.